The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 2, 2004, Pages 114-121

  Konopka, Bozena ^a   Janiec Jankowska, Aneta ^a   Paszko, Zygmunt ^a   Goluda, Marian ^b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

CMYC oncogenes amplification; Endometrial carcinoma; ERBB2; INT2; PTEN gene mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; EVALUATION; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTORS; GENE AMPLIFICATION; GENE FREQUENCY; GENES, ERBB-2; GENES, MYC; HUMANS; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; POLYMERASE CHAIN REACTION; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 1542283575     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0518-7     Document Type: Article

References (41)

1. Ali Lu, Shriml LM, Dean M (1999) Mutational spectra of PTEN/MMAC1 gene tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91:1922-1932
2. Amundadottir LT, Merlino G, Dickson RB (1996) Transgenic mouse model of breast cancer. Breast Cancer Res Treat 39:119-135
3. Beckmann MW, Niederacher D, Köhrer K, Finken-Eigen M, Schröder W, Schnurch G, Bender HG (1996) Oncogene amplification in archival ovarian carcinoma detected by fluorescent differential polymerase chain reaction-a routine analytical approach. Int J Gynecol Cancer 6:291-297
4. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HG, Portengen H, Klijn JG (1995) Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159:11-18
5. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10-17
6. Borst MP, Baker W, Dixon D, Hatch KD, Shingleton HM, Miller DM (1990) Oncogene alterations in endometrial carcinoma. Gynecol Oncol 38:364-366
7. Bussaglia E, del Rio E, Matias-Guiu J, Prat J (2000) PTEN mutations in endometrial carcinoma: a molecular clinicopathologic analysis of 38 cases. Hum Pathol 31:312-317
8. Creasman WT (1989) FIGO stages:1988 revisions. Gynecol Oncol 35:125-127
9. Esteller M, Garcia A, Martinez-Palones JM, Cabero A, Reventos J (1995) Detection of C-erb-2/neu and fibroblast growth factor-3/INT-2 not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 75:2139-2146
10. Frye RA, Benz C, Lin E (1989) Detection of oncogenes by differential polymerase chain reaction. Oncogene 4:1153-1157
11. Ghosh AK, Grigorieva I, Steele R, Hoover RG, Ray RB (1999) PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation. Gene 235:85-91
12. Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K, Matsuno S, Kanamura R, Ishioka Ch (2000) Funcional evaluation of PTEN missense mutation using in vitro phosphoinositide phosphatase assay. Cancer Res 60:3147-3151
13. Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, Goodfellow PJ (2002) Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concominant atypical hyperplasia. Gynecol Oncol 86:62-68
14. Hruza C, Dobianer K, Beck A, Czerwenka K, Hanak H, Klein M, Leodolter S, Medl M, Müllauer-Ertl S, Preiser J, Rosen A, Salzel H, Selveda P, Spona J (1993) Her-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples. Eur J Cancer 29A:1593-1597
15. Inoue M (2001) Current molecular aspects of carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 11:339-348
16. Konopka B, Paszko Z, Janiec-Jankowska A, Goluda M (2002) Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett 178:43-51
17. Koul A, Willen R, Bendahl P-O, Nilbert M, Borg A (2002) Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 94:2369-2379
18. Latta E, Chapman WB (2002) PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59-65
19. Lax SF, Kendal B, Tashiro H, Slebas RJ, Ellenson LH (2000) The frequency of p53, K-ras mutation, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer 88:814-824
20. Lilja JF, Wu D, Reynolds RK, Lin J (2001) Growth suppression activity of the PTEN tumor -suppressor gene in human endometrial cancer cells. Anticancer Res 21:1969-1974
21. Machin P, Catacus L, Pons C, Munoz J, Matias-Guiu X, Prat J (2002) CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 33:206-212
22. Manavi M, Bauer M, Baghestanian M, Berger A, Kucera E, Pischinger K, Battistutti W, Czerwenka K (2001) Oncogenic potential of c-erbB2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium. Tumor Biol 22:299-309
23. Matias-Guiu X, Catacus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32:569-577
24. Menard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N (2002) HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8:520-525
25. Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K, Aketani Y (2001) PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 7:2636-2642
26. Monk BJ, Chapman JA, Johnson GA, Briahtman BK, Wilczynski SP, Schell MJ, Fan H (1994) Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol 171:1193-1198
27. Munger K (2002) Disruption of oncogene/tumor suppressor networks during human carcinogenesis. Cancer Invest 20:71-81
28. Mutter GL (2002) Diagnosis of premalignant endometrial disease. J Clin Pathol 55:326-331
29. Niederacher D, An H-X, Cho Y-J, Hantschmann P, Bender HG, Beckmann MW (1995) Mutations and amplification of oncogenes in endometrial cancer. Oncology 56:59-65
30. Pauley RJ, Gimotty PA, Paine TJ, Dawson PJ, Wolman SR (1996) INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes. Breast Cancer Res Treat 37:65-76
31. Risinger JI, Hayes AK, Maxwell GL, Corney ME, Dodge RK, Barret JC, Berchuck A (1998) PTEN mutations in endometrial cancer is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4:3005-3010
32. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH (1999) HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 18:138-143
33. Sakuragi N, Hirai A, Tada M, Yamada H, Yamamoto R, Fujimoto S, Moriuchi T (2001) Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol 83:485-490
34. Salvesen HB and Akslen A (2002) Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 110:673-689
35. Sambrook J, Fritsh EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
36. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Michatsch MJ, Kallioniemi O-P, Sauter G (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975
37. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ (1994) Histological typing of female genital tract tumors. In: WHO: International histologocal typing of tumors. Springer, New York, pp. 14-31
38. Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13:295-308
39. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935-3940
40. Van Nostrand K, Johnson G, Monk B, Wilczynski S, Chapman J, Brightman K, Schells M, Berman M, Manetta A, Disala P, Fan H (1998) Genetic alterations in endometrial carcinomas. Int J Gynecol Cancer 8:415-422
41. Williams JA Jr, Wang ZR, Parrish RS, Hazlett LJ, Smith ST, Young SR (1999) Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. Exp Mol Pathol 67:135-143